SAMHD1 is a barrier to antimetabolite-based cancer therapies
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 Mar 2017
|
| In: |
Molecular & cellular oncology
Year: 2017, Jahrgang: 4, Heft: 2, Pages: 1-3 |
| ISSN: | 2372-3556 |
| DOI: | 10.1080/23723556.2017.1287554 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1080/23723556.2017.1287554
|
| Verfasserangaben: | Sean G. Rudd, Torsten Schaller and Nikolas Herold |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572536055 | ||
| 003 | DE-627 | ||
| 005 | 20230111094751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180502s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/23723556.2017.1287554 |2 doi | |
| 035 | |a (DE-627)1572536055 | ||
| 035 | |a (DE-576)502536055 | ||
| 035 | |a (DE-599)BSZ502536055 | ||
| 035 | |a (OCoLC)1341008003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rudd, Sean G. |e VerfasserIn |0 (DE-588)1156957001 |0 (DE-627)1019902582 |0 (DE-576)502536721 |4 aut | |
| 245 | 1 | 0 | |a SAMHD1 is a barrier to antimetabolite-based cancer therapies |c Sean G. Rudd, Torsten Schaller and Nikolas Herold |
| 264 | 1 | |c 17 Mar 2017 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 500 | |a Published online 17 May 2017 | ||
| 700 | 1 | |a Schaller, Torsten |e VerfasserIn |0 (DE-588)1155841174 |0 (DE-627)1018325425 |0 (DE-576)501895574 |4 aut | |
| 700 | 1 | |a Herold, Nikolas |d 1985- |e VerfasserIn |0 (DE-588)1070891401 |0 (DE-627)824724852 |0 (DE-576)432801375 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular & cellular oncology |d London : Taylor & Francis, 2014 |g 4(2017), 2, Artikel-ID e1287554, Seite 1-3 |h Online-Ressource |w (DE-627)835890988 |w (DE-600)2835425-4 |w (DE-576)44572093X |x 2372-3556 |7 nnas |a SAMHD1 is a barrier to antimetabolite-based cancer therapies |
| 773 | 1 | 8 | |g volume:4 |g year:2017 |g number:2 |g elocationid:e1287554 |g pages:1-3 |g extent:3 |a SAMHD1 is a barrier to antimetabolite-based cancer therapies |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/23723556.2017.1287554 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180502 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1155841174 |a Schaller, Torsten |m 1155841174:Schaller, Torsten |d 910000 |d 911700 |e 910000PS1155841174 |e 911700PS1155841174 |k 0/910000/ |k 1/910000/911700/ |p 2 | ||
| 999 | |a KXP-PPN1572536055 |e 3007770688 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"SAMHD1 is a barrier to antimetabolite-based cancer therapies","title_sort":"SAMHD1 is a barrier to antimetabolite-based cancer therapies"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Rudd, Sean G.","given":"Sean G.","family":"Rudd"},{"given":"Torsten","family":"Schaller","role":"aut","roleDisplay":"VerfasserIn","display":"Schaller, Torsten"},{"family":"Herold","given":"Nikolas","display":"Herold, Nikolas","roleDisplay":"VerfasserIn","role":"aut"}],"recId":"1572536055","language":["eng"],"note":["Gesehen am 16.04.2020","Published online 17 May 2017"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1572536055"],"doi":["10.1080/23723556.2017.1287554"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"17 Mar 2017"}],"name":{"displayForm":["Sean G. Rudd, Torsten Schaller and Nikolas Herold"]},"relHost":[{"origin":[{"dateIssuedKey":"2014","publisher":"Taylor & Francis","dateIssuedDisp":"2014-","publisherPlace":"London"}],"id":{"eki":["835890988"],"zdb":["2835425-4"],"issn":["2372-3556"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Molecular & cellular oncology","title":"Molecular & cellular oncology"}],"pubHistory":["1.2014 -"],"titleAlt":[{"title":"Molecular and cellular oncology"}],"part":{"text":"4(2017), 2, Artikel-ID e1287554, Seite 1-3","volume":"4","extent":"3","year":"2017","pages":"1-3","issue":"2"},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"SAMHD1 is a barrier to antimetabolite-based cancer therapiesMolecular & cellular oncology","note":["Gesehen am 21.09.2024"],"language":["eng"],"recId":"835890988"}],"physDesc":[{"extent":"3 S."}]} | ||
| SRT | |a RUDDSEANGSSAMHD1ISAB1720 | ||